ALSEN Stock Overview
Sensorion SA, a biotechnology company, develops drug candidates for the treatment of inner ear disorders in France.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Sensorion SA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €0.71 |
| 52 Week High | €1.04 |
| 52 Week Low | €0.26 |
| Beta | 1.32 |
| 1 Month Change | -6.58% |
| 3 Month Change | 1.43% |
| 1 Year Change | 162.48% |
| 3 Year Change | -65.02% |
| 5 Year Change | -41.80% |
| Change since IPO | -84.36% |
Recent News & Updates
Shareholder Returns
| ALSEN | FR Biotechs | FR Market | |
|---|---|---|---|
| 7D | 1.1% | 1.1% | 3.3% |
| 1Y | 162.5% | -17.3% | 6.0% |
Return vs Industry: ALSEN exceeded the French Biotechs industry which returned -15.9% over the past year.
Return vs Market: ALSEN exceeded the French Market which returned 6% over the past year.
Price Volatility
| ALSEN volatility | |
|---|---|
| ALSEN Average Weekly Movement | 9.3% |
| Biotechs Industry Average Movement | 6.7% |
| Market Average Movement | 4.4% |
| 10% most volatile stocks in FR Market | 9.5% |
| 10% least volatile stocks in FR Market | 2.2% |
Stable Share Price: ALSEN's share price has been volatile over the past 3 months.
Volatility Over Time: ALSEN's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of French stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 57 | Nawal Ouzren | www.sensorion.com |
Sensorion SA, a biotechnology company, develops drug candidates for the treatment of inner ear disorders in France. Its pipeline includes various products in the development stage for restoring, treating, and preventing inner ear related disorders. The company’s product portfolio includes SENS-401 SSNHL, which has completed Phase 2 clinical trial for the treatment of Sudden Sensorineural Hearing Loss; SENS-401 CIO that is in Phase 2 clinical trial for the treatment of Cisplatin-Induced Ototoxicity; and SENS-401 Cochlear, which is in Phase 2 clinical trial for the treatment of hearing preservation after cochlear implantation.
Sensorion SA Fundamentals Summary
| ALSEN fundamental statistics | |
|---|---|
| Market cap | €195.61m |
| Earnings (TTM) | -€22.06m |
| Revenue (TTM) | €5.57m |
35.1x
P/S Ratio-8.9x
P/E RatioIs ALSEN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ALSEN income statement (TTM) | |
|---|---|
| Revenue | €5.57m |
| Cost of Revenue | €0 |
| Gross Profit | €5.57m |
| Other Expenses | €27.63m |
| Earnings | -€22.06m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.08 |
| Gross Margin | 100.00% |
| Net Profit Margin | -396.45% |
| Debt/Equity Ratio | 6.0% |
How did ALSEN perform over the long term?
See historical performance and comparison